IRX5010

IRX5010 is a second-generation, highly selective and potent small molecule agonist of the retinoic acid receptor gamma (RARγ), developed by Io Therapeutics. It is being investigated primarily as an oral immunotherapeutic for the treatment of various cancers, including triple negative breast cancer, Her2-positive breast cancer, non-small cell lung cancer, colorectal cancer, and prostate cancer. Preclinical studies have shown that IRX5010 suppresses tumor growth in multiple mouse models by promoting tumor-infiltrating effector memory T lymphocytes (TILs) and inhibiting myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment. These immune-mediated mechanisms are believed to enhance anti-tumor responses rather than exert direct cytotoxic effects on tumor cells. Combination studies with checkpoint inhibitors such as anti-PD-L1 antibodies have demonstrated additive or synergistic effects in preclinical models[1][3][5][6][7].